A new life-extending cancer treatment drug, Dacomitinib, has been recommended as a first-line treatment for people who have a certain type of non-small-cell lung cancer (NSCLC), thanks to new NICE guidelines.

New Treatments

The once a day pill will be available to adults with locally advanced or metastatic NSCLC, who have tested positive for the epidermal growth factor receptor (EGFR) mutation. This is a change from the committee’s original decision, which found Dacomitinib not to be a cost-effective use of NHS resources.